pharma · MASH · MASLD · SGMT
Sagimet Biosciences
Sagimet Biosciences is a pharma organization headquartered in San Mateo, USA. It trades on NYSE under ticker SGMT. Primary therapeutic focus areas include MASH, MASLD, Metabolic Syndrome, Non-alcoholic Steatohepatitis, K
155 Bovet Rd, Suite 303, San Mateo, California 94402, US HQ
27 Employees
Public company Type
SGMT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 155 Bovet Rd, Suite 303, San Mateo, California 94402, US
- Employees
- 27
- Programs
- 12
- Drugs
- 4
- Patents
- 1
TVB-2640 25 mg (US)
Phase 2 · small molecule · MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
TVB-2640 25 mg (US) for MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) is a Phase 2 program (small_molecule) at Sagimet Biosciences with 1 ClinicalTrials.gov record(s).
Internal code 3V2640-CLIN-005
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sagimet Biosciences
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
- Status
- completed
- Trials
- 1